Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the effect of a lifestyle intervention to produce weight loss and increased physical fitness on use and cost of medications to treat cardiovascular disease (CVD) risk factors in people with type 2 diabetes. RESEARCH DESIGN AND METHODS: Look AHEAD is a multicenter randomized controlled trial of 5,145 overweight or obese individuals with type 2 diabetes, aged 45–76 years. An intensive lifestyle intervention (ILI) involving group and individual meetings to achieve and maintain weight loss through decreased caloric intake and increased physical activity was compared with a diabetes support and education (DSE) condition. Medications prescribed to treat diabetes, hypertension, and hyperlipidemia were compared at baseline and 1 year. Medication costs were conservatively estimated using prices from a national online pharmacy. RESULTS: Participants randomized to an ILI had significantly greater improvements in CVD risk parameters and reduced medication use and cost compared with those assigned to DSE. At 1 year, average number of medications prescribed to treat CVD risk factors was 3.1 ± 1.8 for the ILI group and 3.6 ± 1.8 for the DSE group (P < 0.0001), with estimated total monthly medication costs of $143 and $173, respectively (P < 0.0001). DSE participants meeting optimal care goals at 1 year were taking an average of 3.8 ± 1.6 medications at an estimated cost of $194/month. ILI participants at optimal care required fewer medications (3.2 ± 1.7) at lower cost ($154/month) (P < 0.001). CONCLUSIONS: At 1 year, ILI significantly improved CVD risk factors, while at the same time reduced medication use and cost. Continued intervention and follow-up will determine whether these changes are maintained and reduce cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522 · cited 3×
“The one year results of the Look AHEAD intensive lifestyle intervention (ILI) on weight loss, glycemic control, blood pressure, lipid parameters and medication use were recently reported (14).”
BackgroundMethodInfluentialStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Economic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
A systematic review of adherence with medications for diabetes
Cramer, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1218 · Cited by 1,203
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
The Look AHEAD Research Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00064-3 · Cited by 767 · cited 2×
“In these instances, the study protocol provided that hyperglycemic medications would be returned to the original regimen when the period of the intensive caloric restriction was completed (16).”
BackgroundMethodForecasting the effects of obesity and smoking on U.S. life expectancy
Stewart, S. T., Cutler, D. M., & Rosen, A. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0900459 · Cited by 478
Franco, O. H., Steyerberg, E. W., Hu, F. B., Mackenbach, J., & Nusselder, W. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.11.1145 · Cited by 400 · cited 1×
“People with type 2 diabetes die on average 8 years earlier than their nondiabetic counterparts, primarily due to a two- to fourfold increased risk of CVD (2,19).”
BackgroundNon-HDL Cholesterol as a Predictor of Cardiovascular Disease in Type 2 Diabetes
Lu, W., Resnick, H. E., Jablonski, K. A., Jones, K. L., Jain, A. K., Howard, W. J., Robbins, D. C., & Howard, B. V. (2003) · Diabetes Care · doi:10.2337/diacare.26.1.16 · Cited by 370
Bray, G. A. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.031 · Cited by 158
Cited by
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70156-1 · Cited by 319
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Understanding the mechanisms of reversal of type 2 diabetes
Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299
Johansen, M. Y., MacDonald, C. S., Hansen, K. B., Karstoft, K., Christensen, R., Pedersen, M., Hansen, L. S., Zacho, M., Wedell-Neergaard, A.-S., Nielsen, S. T., et al. (2017) · JAMA · doi:10.1001/jama.2017.10169 · Cited by 244
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
Metadata
- Authors
- Redmon, J. B., Bertoni, A. G., Connelly, S., Feeney, P. A., Glasser, S. P., Glick, H., Greenway, F., Hesson, L. A., Lawlor, M. S., Montez, M., Montgomery, B., & the Look AHEAD Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-23
- Volume
- 33
- Issue
- 6
- Pages
- 1153-1158
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2108978856
- Cited by
- 115
- References
- 13
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.